In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $3.91. According to TipRanks, Argyrides is a 4-star analyst with an average return of 14.4% and a 49.28% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Verona Pharma, Aerovate Therapeutics, and BioMarin Pharmaceutical. Currently, the analyst consensus on Unity Biotechnology is a Moderate Buy with an average price target of $23.50. See the top stocks recommended by analysts >> UBX market cap is currently $55.49M and has a P/E ratio of -0.50.
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.  Read More on UBX: Indices Commodities Currencies Stocks